Management of Respiratory Failure Type II with Salbutamol

Indications and Administration

For patients with type II respiratory failure, nebulized salbutamol (2.5-5 mg) should be administered via air-driven nebulizer every 4-6 hours, with careful monitoring of arterial blood gases to prevent worsening carbon dioxide retention 1, 2, 3
The American Thoracic Society recommends salbutamol for acute exacerbations of COPD with bronchospasm 1
Salbutamol is indicated for the management of bronchospasm in respiratory failure 3
Relief of bronchospasm in patients with reversible obstructive airway disease can be achieved with salbutamol 1, 2

Hypersensitivity to salbutamol or any component of the formulation is a contraindication 2
Caution should be exercised in patients with cardiovascular disorders, especially coronary insufficiency and hypertension 4
Caution is also advised in patients with convulsive disorders or hyperthyroidism, although the evidence is not strongly supported by the provided citations

Assess respiratory status before and after administration to establish baseline and evaluate treatment effectiveness 1
Monitor arterial blood gases critically in type II respiratory failure to detect worsening carbon dioxide retention 2, 3
Use air (not oxygen) to drive nebulizer to avoid worsening hypercapnia in type II respiratory failure patients 4, 5
Maintain proper nebulizer technique to ensure optimal drug delivery to the lower airways 4, 5
Position patient upright during nebulization to maximize lung expansion and medication distribution 4
Clean nebulizer equipment properly after each use to prevent infection and ensure proper functioning 4
Document response to treatment to evaluate effectiveness and guide future treatment decisions 1
Educate patient about possible side effects to improve compliance and reduce anxiety 4

In patients with carbon dioxide retention and acidosis, the nebulizer must be driven by air, not oxygen, to prevent worsening hypercapnia 1, 2
Combined treatment with ipratropium bromide (250-500 μg) should be considered in more severe cases, especially if the patient has had a poor response to salbutamol alone 2